Securities Code: 002365 Securities Abbreviation: An'an Pharmaceutical Announcement No.: 2026-24
Jingmen An'an Pharmaceutical Co., Ltd. Announcement on the Use of Own Funds for Entrusted Wealth Management
The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false representations, misleading statements, or material omissions.
Key Content Reminder:
- Investment Type: Entrusted wealth management includes entrusting banks, trusts, securities, funds, futures, insurance asset management institutions, financial asset investment companies, fund managers, and other professional wealth management institutions to invest and manage their assets or purchase relevant wealth management products.
- Investment Amount: The total amount of own funds used by the Company and its subsidiaries for entrusted wealth management shall not exceed RMB 700 million (inclusive). The funds can be rolled over within this limit.
- Special Risk Reminder: Although the wealth management products invested in by the Company are generally low-to-medium risk investment products, the Company will conduct strict evaluations before implementation and will intervene in a timely and appropriate manner based on economic conditions and changes in the financial market. However, the financial market is significantly affected by the macroeconomic environment, and investments in wealth management projects are not excluded from the possibility of affecting expected returns due to market risk, policy risk, liquidity risk, force majeure risk, and other risk factors. Investors are kindly reminded to pay attention to investment risks.
To improve the utilization efficiency and returns of the idle funds of Jingmen An'an Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), and to obtain certain investment returns, the Company held the 15th meeting of the 7th Board of Directors on April 29, 2026, and deliberated and approved the "Proposal on the Use of Own Funds for Entrusted Wealth Management." It was agreed that the Company and its subsidiaries would use a total of no more than RMB 700 million (inclusive) of their own funds for entrusted wealth management. The above limit can be used on a rolling basis, with a validity period of no more than 12 months from the date of approval by the shareholders' meeting. The management is authorized to implement the relevant matters. The details are as follows:
I. Overview of Entrusted Wealth Management
- Overview The Company held the 6th extraordinary meeting of the 7th Board of Directors on April 28, 2025, and the 2024 Annual Shareholders' Meeting on June 24, 2025, respectively. The "Proposal on the Use of Own Funds for Entrusted Wealth Management" was deliberated and approved, agreeing that the Company and its subsidiaries would use a total of no more than RMB 750 million (inclusive) of their own funds for entrusted wealth management.